SUNDANC3

Portfolio manager

[Michele @mic_h_el]

Interesting note by @statnews PARP for Parkinson’s? $CLVS

[The Science of Parkinson's @ScienceofPD]

The latest post on the SoPD website looks at the potential use of a class of drugs called PARP inhibitors in #Parkinsons
https://t.co/dvxE2mTUgn

[Andy Biotech @AndyBiotech]

Very interesting! --> $CLVS $TSRO $AZN $PFE

PARPi as potential disease-modifying therapy for #Parkinson's disease
https://t.co/Hsvz38rEh1

https://t.co/d3MIPddHc5

[OneMdcn @OneMdcn]

$ONCY Oncolytics Biotech® Announces a Publication Demonstrating That Intravenously Delivered Oncolytic Viruses Effectively Target Tumors Even in the Presence of Neutralizing Antibodies

Click here to read the full article

[OneMdcn @OneMdcn]

$ONCY Study of Pembrolizumab With REOLYSIN® and Chemotherapy in Patients With Advanced Pancreatic Adenocarcinoma

Update: Study Status: Completed
Latest version (September 12, 2018) on https://t.co/IIX03doFnu

[OneMdcn @OneMdcn]

$ONCY # Reovirus

Going (Reo)Viral: Factors Promoting Successful Reoviral Oncolytic Infection

https://t.co/xO8LHou0QC

[SUNDANC3 @Sundanc31]

Cancer-killing viruses show promise — and draw billion-dollar investment https://t.co/4nQ0szC8yE

[Seeking Alpha @SeekingAlpha]

$AERI $LLY $RNN https://t.co/HdKx1xw8V0

[Bio Stocks™ @BioStocks]

$ONCYF Announces Collaboration with $MRK and Northwestern University Combining Keytruda and REOLYSIN in a Phase 2 Second Line Pancreatic Cancer Study

[Giles @ahighelevation]

$ONCYF 20 Nickels or $1; NASDAQ Listing Coming https://t.co/HZdGwnf8w9 $ONCYF @Oncolytics #biotech @vanjohn10

[SUNDANC3 @Sundanc31]

@mariebender Bientôt 10 tweets sur la #pdg18 pendant l'événement.Cela ressemble davantage à un appel au secours qu'à une véritable critique du ski alpinisme. Tentez une aventure pour partir à la découverte de vous-même plutôt que de vouloir attirer l'attention sur celle que vous n'êtes pas

[YVR τrader @YVR_Trader]

$ONCYF $ONC.to at #AACR2018 #AACR18 https://t.co/HZK1htz2DC

[Zacks SCR @ZacksSmallCap]

$ONCYF: A Whirlwind 2017 Readies Spate of New Trials @Oncolytics https://t.co/XaP1PauA07 - by @vanjohn10

[SUNDANC3 @Sundanc31]

$rnn 200'000 shares Insider Trading
https://t.co/vYjh4oWsHf

[SUNDANC3 @Sundanc31]

@preston97979797 @Xofigo in addition to prolonging survival, Ra-223 reduces pain and opioid use in patients with CRPC and bone metastases. https://t.co/eRTvvaN3el

[MichaelSDeVries @MichaelSDeVries]

$RNN Rexahn Pharmaceuticals, Inc. (RNN) Rating Increased to #Buy, $2.25 PT, at Zacks: https://t.co/vp5J12HD4p #Rexahn #Pharmaceuticals #RNN

[Watchlist News @WatchlistN]

Rexahn Pharmaceuticals, Inc. $RNN Lifted to Buy at Zacks Investment Research https://t.co/spB3TUDHfu